Loading data for TYRA — first visit, this takes a few seconds.

알림

Tyra Biosciences Inc. (TYRA)

NasdaqGS: TYRA · 실시간 가격 · USD

26.55

+0.51 (1.96%)

종가 기준: Aug 19, 2026, 2:17 PM

1.96% (1D)

매수호가	19.26
시가총액	1.55B
매출 (ttm)	n/a
순이익 (ttm)	-148.56M
베타	0.77
EPS (ttm)	-2.37
P/E (ttm)	n/a
선행 P/E	-8.79
P/B (ttm)	5.40
P/S (ttm)	n/a
Earnings Date	Nov 4, 2026

매도호가	34.16
거래량	94,570
평균 거래량 (20일)	821,703
시가	26.69
전일 종가	26.04
일중 범위	26.27 - 26.98
52주 범위	9.96 - 40.65
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

TYRA 소개

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clin...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Sep 15, 2021

직원 수 87

상장 거래소 NasdaqGS

티커 TYRA

웹사이트 https://tyra.bio

전체 기업 정보

재무 실적

2025년 Tyra Biosciences의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -119.95M로, 38.7% 증가했습니다.

재무제표

어닝 서프라이즈

Tyra Biosciences가 Aug 4, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.69 예상치 하회 -0.05, 및 -46.81% 전년 대비 감소.

다음 실적 발표

Tyra Biosciences Inc.의 실적 발표 예정일은 Nov 4, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1개월 전 · Insider Monkey

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the most promising stocks on our list. TheFly repor...

2개월 전 · Simply Wall St.

Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?

Recently, analysts issued mixed commentary on Tyra Biosciences, balancing optimism around its FGFR3 inhibitor dabogratinib and a new board appointment with renewed questions about the SURF-302 program...

2개월 전 · MT Newswires

Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says

Tyra Biosciences' (TYRA) weak investor sentiment reflects a mix of macro pressures, profit-taking, a

2개월 전 · Insider Monkey

Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the 10 Best Russell 2000 Stocks to Invest In According to Hedge Funds. On May 19, Wolfe Research initiated Tyra Biosciences, Inc. (NASDAQ:TYRA) with a Pe...

3개월 전 · Motley Fool

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.

2 페이지 중 1

Tyra Biosciences Inc. (TYRA)